Cilostazol-induced acute tubulointerstitial nephritis accompanied by IgA nephropathy: a case report
Background Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as
Hisato Shima +7 more
doaj +1 more source
Cilostazol prevents endothelin-induced smooth muscle constriction and proliferation. [PDF]
Cilostazol is a phosphodiesterase inhibitor that has been shown to inhibit platelet activation. Endothelin is known to be the most potent endogenous growth promoting and vasoactive peptide.
Yoshifumi Kawanabe +6 more
doaj +1 more source
Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:Pooled analysis of randomized trials [PDF]
Background and Purpose: Lacunar stroke accounts for ≈25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear.
Benavente, Oscar R. +5 more
core +1 more source
Cilostazol Suppresses IL-23 Production in Human Dendritic Cells via an AMPK-Dependent Pathway
Background/Aims: Cilostazol has been previously demonstrated to inhibit IL-23 production in human synovial macrophages via a RhoA/ROCK-dependent pathway.
Quanxing Shi +9 more
doaj +1 more source
Cilostazol Upregulates Autophagy via SIRT1 Activation: Reducing Amyloid-β Peptide and APP-CTFβ Levels in Neuronal Cells. [PDF]
Autophagy is a vital pathway for the removal of β-amyloid peptide (Aβ) and the aggregated proteins that cause Alzheimer's disease (AD). We previously found that cilostazol induced SIRT1 expression and its activity in neuronal cells, and thus, we ...
Hye Rin Lee +8 more
doaj +1 more source
Cilostazol reduces restenosis after carotid artery stenting [PDF]
BACKGROUND: Although carotid artery stenting (CAS) has been proposed as an alternative to carotid endarterectomy in cerebral revascularization, restenosis remains an unsolved issue.
Hayakawa Mikito +6 more
core +1 more source
BackgroundCilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, is known as an anti-platelet drug and acts directly on platelets. Cilostazol has been shown to exhibit vascular protection in ischemic diseases. Although vascular endothelium-derived
Ayako Hashimoto +4 more
doaj +1 more source
ESVM Guideline on peripheral arterial disease [PDF]
International ...
+38 more
core +5 more sources
A simple, rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLCâMS/MS) method has been developed for the simultaneous determination of cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in
Nejal M. Bhatt +5 more
doaj +1 more source
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats [PDF]
PURPOSE: To evaluate effects of ischemic preconditioning and Cilostazol on muscle ischemia-reperfusion injury.METHODS: Male Wistar rats were submitted to muscle ischemic and reperfusion injury (4h of the left common iliac artery occlusion followed by 1h ...
Frias Neto, Carlos Alberto da Silva +4 more
core +3 more sources

